American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1379)
  9. Gastrointestinal Oncology Service (1353)
  10. Hematologic Malignancies, Division of (1281)
Search Within
Formats
  1. Meeting Abstract (6334)
  2. Journal Article (2579)
  3. Editorial (76)
  4. Review (68)
  5. Guidelines (54)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6399)
  2. Solid Tumor Oncology Division (5537)
  3. Survivorship Research (1997)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1637)
  6. Epidemiology and Biostatistics (1495)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (306)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (275)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8694)
  2. JCO Precision Oncology (171)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (53)
  6. JCO Oncology Practice (7)

More Publications

Results (9167)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-in-human study of RLY-2608, a pan-mutant and isoform selective PI3Kα inhibitor, as a single agent in patients (pts) with advanced solid tumors and in combination with fulvestrant in pts with advanced breast cancer
    Meeting Abstract

    Saura, C.; Sanz, L.; Kim, J.; Jhaveri, K. L.; Guerrero, A.; Ortega, P. T.; Schott, A. F.; Curigliano, G.; Perez, C. A.; Nanda, R.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation
    Meeting Abstract

    Goetz, M. P.; Wander, S. A.; Bachelot, T.; Batist, G.; Cortes, J.; Cristofanilli, M.; Curigliano, G.; De Nonneville, A.; Gal-Yam, E. N.; Jhaveri, K. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Preliminary safety, pharmacokinetics and clinical activity of DFF332, an oral HIF2α inhibitor, as monotherapy in a phase 1 dose escalation study in patients with advanced clear cell renal cell carcinoma
    Meeting Abstract

    Pal, S. K.; Tannir, N. M.; Grell, P.; Gao, X.; Kotecha, R. R.; Picus, J.; De Braud, F. G.; Takahashi, S.; Wong, A.; Suarez, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (OPBC-03/SAKK 23/16/IBCSG 57-18/ABCSG-53/GBG-101-TAXIS)
    Meeting Abstract

    Weber, W. P.; Matrai, Z.; Hayoz, S.; Tausch, C.; Henke, G.; Zimmermann, F.; Montagna, G.; Fitzal, F.; Gnant, M.; Ruhstaller, T.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤ 18 breast cancer
    Meeting Abstract

    White, J. R.; Cecchini, R. S.; Harris, E. E.; Mamounas, E. P.; Stover, D. G.; Ganz, P. A.; Jagsi, R.; Anderson, S. J.; Bergom, C.; Theberge, V.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Lenvatinib plus pembrolizumab (L plus P) vs sunitinib (S) in advanced renal cell carcinoma (aRCC): Patterns of progression and subsequent therapy in the CLEAR trial
    Meeting Abstract

    Grünwald, V.; Motzer, R. J.; Keizman, D.; Bedke, J.; Schmidinger, M.; Staehler, M. D.; Matveev, V. B.; George, S.; Hutson, T. E.; Vaishampayan, U. N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy, safety, and determination of RP2D of ABBV-383, a BCMA bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM)
    Meeting Abstract

    Valdes, C. R.; Voorhees, P. M.; D'Souza, A.; Chung, A.; Tuchman, S.; Safah, H.; McKay, J. T.; Weisel, K. C.; Teipel, R.; Korde, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER)
    Meeting Abstract

    Strickler, J. H.; Cercek, A.; Siena, S.; Andre, T.; Ng, K.; Van Cutsem, E.; Wu, C.; Paulson, A. S.; Hubbard, J. M.; Coveler, A. L.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Efficacy of erdafitinib in adults with advanced solid tumors and non-prespecified fibroblast growth factor receptor mutations in the phase 2 RAGNAR trial: Exploratory cohort
    Meeting Abstract

    Lugowska, I. A.; Schuler, M. H.; Loriot, Y.; Carranza, O.; Iyer, G.; Doi, T.; Qin, S.; Tabernero, J.; Reardon, D. A.; Massard, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Meeting Abstract

    Elimova, E.; Shitara, K.; Moehler, M. H.; Ajani, J. A.; Shen, L.; Garrido, M.; Gallardo, C.; Wyrwicz, L. S.; Yamaguchi, K.; Cleary, J. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save